Evidence map›Paper›PMID 32360484›Full record

ArticlePharmacological research2020

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.

Ruocong Yang, Hao Liu, Chen Bai, Yingchao Wang, Xiaohui Zhang, Rui Guo, Siying Wu, Jianxun Wang, Elaine Leung, Hang Chang and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 5 pooled it
34.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 5 syntheses or guidelines pooled it, 223 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Ruocong YangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing, 100029, China.
Hao LiuPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Chen BaiSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing, 100029, China.
Yingchao WangPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Xiaohui ZhangPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Rui GuoPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Siying WuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing, 100029, China.
Jianxun WangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing, 100029, China.
Elaine LeungMacau University of Science & Technology, Macau, China.
Hang ChangLawrence Berkeley National Laboratory, University of California, USA.
Peng LiSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing, 100029, China.
Tiegang LiuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing, 100029, China. Electronic address: liutg@bucm.edu.cn.
Yi WangPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. Electronic address: zjuwangyi@zju.edu.cn.
Beijing University of Chinese Medicine · CNZhejiang University · CNZhejiang Pharmaceutical College · CNLawrence Berkeley National Laboratory · USMacau University of Science and Technology · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic has become a huge threaten to global health, which raise urgent demand of developing efficient therapeutic strategy. The aim of the present study is to dissect the chemical composition and the pharmacological mechanism of Qingfei Paidu Decoction (QFPD), a clinically used Chinese medicine for treating COVID-19 patients in China. Through comprehensive analysis by liquid chromatography coupled with high resolution mass spectrometry (MS), a total of 129 compounds of QFPD were putatively identified. We also constructed molecular networking of mass spectrometry data to classify these compounds into 14 main clusters, in which exhibited specific patterns of flavonoids (45 %), glycosides (15 %), carboxylic acids (10 %), and saponins (5 %). The target network model of QFPD, established by predicting and collecting the targets of identified compounds, indicated a pivotal role of Ma Xing Shi Gan Decoction (MXSG) in the therapeutic efficacy of QFPD. Supportively, through transcriptomic analysis of gene expression after MXSG administration in rat model of LPS-induced pneumonia, the thrombin and Toll-like receptor (TLR) signaling pathway were suggested to be essential pathways for MXSG mediated anti-inflammatory effects. Besides, changes in content of major compounds in MXSG during decoction were found by the chemical analysis. We also validate that one major compound in MXSG, i.e. glycyrrhizic acid, inhibited TLR agonists induced IL-6 production in macrophage. In conclusion, the integration of in silico and experimental results indicated that the therapeutic effects of QFPD against COVID-19 may be attributed to the anti-inflammatory effects of MXSG, which supports the rationality of the compatibility of TCM.

Indexed as

AnimalsAnti-Inflammatory AgentsBetacoronavirusCells, CulturedComputer SimulationCoronavirus InfectionsCOVID-19Drugs, Chinese HerbalGene ExpressionGlycyrrhizic AcidHumansInterleukin-6LipopeptidesLipopolysaccharidesMalePandemicsAnti-Inflammatory AgentsDrugs, Chinese HerbalGlycyrrhizic AcidInterleukin-6LipopeptidesLipopolysaccharidesmaxingshiganPam(3)CSK(4) peptideqingfei paidu decoctionThrombinToll-Like ReceptorsAmygdalin (PubChem CID: 656516)Baicalin (PubChem CID: 64982)Corona virus disease 2019Ephedrine (PubChem CID: 9294)Glycyrrhizic acid (PubChem CID: 14982)Hesperidin (PubChem CID: 10621)Ma Xing Shi Gan DecoctionNarirutin (PubChem CID: 442431)Neohesperidin (PubChem CID: 442439)Network pharmacologyQingfei Paidu DecoctionTraditional Chinese medicine

Identifiers

PMID32360484
PMCPMC7194979
OpenAlexW3019096936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.